| Literature DB >> 30686906 |
Hans Friedrich Fuchs1, Benjamin Babic2, Karl-Hermann Fuchs3, Wolfram Breithaupt4, Gabor Varga4, Frauke Musial5.
Abstract
BACKGROUND: The clinical presentation of gastroesophageal reflux disease (GERD) shows a large symptom variation also in different intensities among patients. As several studies have shown, there is a large overlap in the symptomatic spectrum between proven GERD and other disorders such as dyspepsia, functional heartburn and/or somatoform disorders. AIM: To prospectively evaluate the GERD patients with and without somatoform disorders before and after laparoscopic antireflux surgery.Entities:
Keywords: Antireflux surgery; Gastroesophageal reflux disease; Gastroesophageal reflux disease symptoms; Laparoscopic fundoplication; Somatization
Mesh:
Year: 2019 PMID: 30686906 PMCID: PMC6343096 DOI: 10.3748/wjg.v25.i3.388
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Figure 1Incidence of somatoform symptoms in patients with gastroesophageal reflux disease. Group A: patients with indication for surgery, willing to undergo surgery. The percentage of SSI ≥ 17 was 22%; Group B: Patients with GERD and indication for surgery, who has refused antireflux surgery and have continued protonpump inhibitors therapy. The percentage of SSI ≥ 17 was 20%. GERD: Gastroesophageal reflux disease; SSI: Somatoform Symptom Index.
Figure 2Preoperative quality of life, as measured by the Gastrointestinal Quality of Life Index in patients with gastroesophageal reflux disease alone (median GIQLI: 105) and patients with gastroesophageal reflux disease and associated somatoform tendencies (SSI ≥ 17) (median GIQLI: 77). This difference is significant (P < 0.001). SSI: Somatoform Symptom Index; GIQLI: Gastrointestinal Quality of Life Index; GERD: Gastroesophageal reflux disease.
Figure 3Pre-and post-therapeutic quality of life, as measured by the Gastrointestinal Quality of Life Index, for both groups. Group A after laparoscopic antireflux surgery (GIQLI preop: 91; postop 117; P < 0,001) and Group B after continued conservative treatment (GIQLI pre: 96; post: 98; P = 0.8279). In the surgical group, GIQLI could be significantly increased. GIQLI: Gastrointestinal Quality of Life Index.
Figure 4Comparison of pre- and postoperative levels of Gastrointestinal Quality of Life Index in relation to the presence of somatoform disorders. Patients with somatoform disorders will also improve their GIQLI postoperatively (GIQLI preop: 75; postop: 95; P < 0.0043), however it could not be increased to normal levels due to the large number of non-related symptoms. Patients with SSI < 17 could reach normal levels of GIQLI postoperatively (preop: 102; postop: 117; P < 0.001). GIQLI: Gastrointestinal Quality of Life Index; SSI: Somatoform Symptom Index; GERD: Gastroesophageal reflux disease.